EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes of ESBL status among UTI admissions: a retrospective analysis of the Nationwide Inpatient Sample from 2016 to 2022

Sun Young Guwn, Reesha Yadav, Eli Blaney, Saif Zurob, Julia Russolillo, Abubakar Tauseef, Mohsin Mirza

Infection · 11.11.2026

DOI: 10.1007/s15010-026-03047-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection, online erschienen am 11.11.2026. Verfasst von Sun Young Guwn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Creighton University School of Medicine, Omaha, NE, USA. sunyoungguwn@creighton.edu. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Extended-spectrum beta-lactamase (ESBL) producing organisms are an increasing cause of urinary tract infections (UTIs) and pose significant challenges to inpatient management due to antimicrobial resistance and limited treatment options. Prior studies focus on prevalence and resistance patterns, but nationally representative inpatient outcome data are lacking. This study assesses the association of ESBL status on clinical outcomes among hospitalized adults with UTIs in the United States.

Methods

A retrospective cohort study was conducted using the Nationwide Inpatient Sample (NIS) from 2016 to 2022. Adult patients aged ≥ 18 years hospitalized with a primary diagnosis of UTI were included. ESBL status was identified using ICD-10-CM code Z16.12, with non-ESBL UTIs serving as the comparison group. The primary outcome was in-hospital mortality, while secondary outcomes included hospital length of stay (LOS) and total inflation-adjusted hospital costs. Propensity score stratification and multivariable regression adjusted for demographic, clinical, and hospital confounders.

Results

Among 1,844,239 UTI hospitalizations from 2016 to 2022, 63,190 (3.4%) involved ESBL-producing organisms. ESBL status was not associated with increased in-hospital mortality compared with non-ESBL UTIs. However, ESBL infections were associated with longer hospital stays (mean difference 1.0 days; 95% CI 0.93 to 1.10; p < 0.001) and higher total hospital charges (mean difference $9,179; 95% CI $8,101 to $10,257; p < 0.001).

Conclusions

In this nationally representative analysis, ESBL-producing UTIs were associated with increased healthcare utilization but not higher in-hospital mortality. These findings highlight the clinical and economic burden of ESBL infections and the importance of targeted prevention and optimized inpatient management strategies.

Schlagwörter

Stichwörter der Autor:innen

Extended-spectrum beta-lactamaseMortalityNational inpatient sampleResource utilizationUrinary tract infections

Autor:innen und Institutionen

  • Creighton University School of Medicine, Omaha, NE, USA. sunyoungguwn@creighton.edu.
  • Creighton University School of Medicine, Omaha, NE, USA.
  • Department of Medicine, Creighton University School of Medicine, Omaha, NE, USA.

Zitieren

APA

Guwn, S. Y., Yadav, R., Blaney, E., Zurob, S., Russolillo, J., Tauseef, A., & Mirza, M. (2026). Outcomes of ESBL status among UTI admissions: a retrospective analysis of the Nationwide Inpatient Sample from 2016 to 2022. Infection. https://doi.org/10.1007/s15010-026-03047-8

Vancouver

Guwn SY, Yadav R, Blaney E, Zurob S, Russolillo J, Tauseef A, et al. Outcomes of ESBL status among UTI admissions: a retrospective analysis of the Nationwide Inpatient Sample from 2016 to 2022. Infection. 2026. doi:10.1007/s15010-026-03047-8

BibTeX
@article{Guwn2026,
  author = {Guwn, Sun Young and Yadav, Reesha and Blaney, Eli and Zurob, Saif and Russolillo, Julia and Tauseef, Abubakar and Mirza, Mohsin},
  title = {Outcomes of ESBL status among UTI admissions: a retrospective analysis of the Nationwide Inpatient Sample from 2016 to 2022},
  journal = {Infection},
  year = {2026},
  doi = {10.1007/s15010-026-03047-8}
}
Kostenlos starten →